Institutional members access full text with Ovid®

ECT Remission Rates in Psychotic Versus Nonpsychotic Depressed Patients: A Report from CORE

Petrides, Georgios M.D.*; Fink, Max M.D.*; Husain, Mustafa M. M.D.†; Knapp, Rebecca G. Ph.D.‡; Rush, A. John M.D.†; Mueller, Martina M.S.‡; Rummans, Teresa A. M.D.§; O'Connor, Kevin M. M.D.§; Rasmussen, Keith G. Jr. M.D.§; Bernstein, Hilary J. M.S.W.‡; Biggs, Melanie Ph.D.†; Bailine, Samuel H. M.D.*; Kellner, Charles H. M.D.‡

Original Articles

Objective: To compare the relative efficacy of electroconvulsive therapy (ECT) in psychotic and nonpsychotic patients with unipolar major depression.

Methods: The outcome of an acute ECT course in 253 patients with nonpsychotic (n = 176) and psychotic (n = 77) unipolar major depression was assessed in the first phase of an ongoing National Institute of Mental Health-supported four-hospital collaborative study of continuation treatments after successful ECT courses. ECT was administered with bilateral electrode placement at 50% above the titrated seizure threshold. The remission criteria were rigorous: a score ≤10 on the 24-item Hamilton Rating Scale for Depression (HRSD) after 2 consecutive treatments, and a decrease of at least 60% from baseline.

Results: The overall remission rate was 87% for study completers. Among these, patients with psychotic depression had a remission rate of 95% and those with nonpsychotic depression, 83%. Improvement in symptomatology, measured by the HRSD, was more robust and appeared sooner in the psychotic patients compared with the nonpsychotic patients.

Conclusion: Bilateral ECT is effective in relieving severe major depression. Remission rates are higher and occur earlier in psychotic depressed patients than in nonpsychotic depressed patients. These data support the argument that psychotic depression is a distinguishable nosological entity that warrants separate treatment algorithms.

*Research Department, Hillside Hospital, North Shore–Long Island Jewish Health System, Glen Oaks, New York; †Department of Psychiatry, University of Texas South Western Medical Center, Dallas, Texas; ‡Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina; and §Department of Psychiatry, Mayo Clinic, Rochester, Minnesota, U.S.A.

From the Consortium for Research in ECT (CORE), a collaboration of the Medical University of South Carolina in Charleston (Charles Kellner, M.D., Principal Investigator, Hilary Bernstein, M.S.W., Rebecca Knapp, Ph.D.); Mayo Clinic in Rochester, MN (Teresa Rummans, M.D., PI, Kevin O'Connor, M.D., Keith Rasmussen, M.D., Glenn Smith, Ph.D.); Hillside Hospital, North Shore–Long Island Jewish Health System in NY (Georgios Petrides, M.D., PI, Max Fink, M.D., Samuel Bailine, M.D., Irene Carasiti, B.S.); and the University of Texas South Western Medical Center at Dallas (Mustafa Husain, M.D., PI, John Rush, M.D., Melanie Biggs, Ph.D., Diane Stegman, R.N.C.).

Received September 6, 2001; accepted September 18, 2001.

Address correspondence to Dr. G. Petrides, Research Department, Hillside Hospital, 75-59 263rd St., Glen Oaks, NY 11004, U.S.A. E-mail: petrides@lij.edu

No member of any research study team has a financial relationship with the manufacturer of any ECT device.

© 2001 Lippincott Williams & Wilkins, Inc.